Gregory Everson
Overview
Explore the profile of Gregory Everson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
763
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poordad F, Bennett M, Sepe T, Cohen E, Reindollar R, Everson G, et al.
J Med Virol
. 2019 Mar;
91(7):1307-1312.
PMID: 30840774
Introduction: Despite high efficacy of current direct-acting antiviral agents (DAAs) in treating chronic hepatitis C virus (HCV) infection, a small portion of patients fail treatment. QUARTZ-I was a phase 2,...
2.
Gane E, Kowdley K, Pound D, Stedman C, Davis M, Etzkorn K, et al.
Gastroenterology
. 2016 Aug;
151(5):902-909.
PMID: 27486033
Background & Aims: Studies are needed to determine the optimal regimen for patients with chronic hepatitis C virus (HCV) genotype 2, 3, 4, or 6 infections whose prior course of...
3.
Forns X, Poordad F, Pedrosa M, Berenguer M, Wedemeyer H, Ferenci P, et al.
Liver Int
. 2015 Aug;
35(11):2358-62.
PMID: 26248955
Background & Aims: Thrombocytopaenia and hypoalbuminaemia are surrogate markers for portal hypertension and hepatic synthetic dysfunction respectively. Patients infected with hepatitis C virus (HCV) with these surrogates have reduced likelihood...
4.
Muir A, Poordad F, Lalezari J, Everson G, Dore G, Herring R, et al.
JAMA
. 2015 May;
313(17):1736-44.
PMID: 25942724
Importance: Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. Objective: All-oral therapy with daclatasvir (nonstructural protein 5A [NS5A]...
5.
Jensen D, Sherman K, Hezode C, Pol S, Zeuzem S, de Ledinghen V, et al.
J Hepatol
. 2015 Feb;
63(1):30-7.
PMID: 25703086
Background & Aims: Improved therapies for peginterferon/ribavirin null or partial responders are needed. This study evaluated daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor) plus peginterferon alfa-2a and ribavirin in...
6.
Emond J, Fisher R, Everson G, Samstein B, Pomposelli J, Zhao B, et al.
Liver Transpl
. 2014 Dec;
21(2):151-61.
PMID: 25488878
Previous reports have drawn attention to persistently decreased platelet counts among liver donors. We hypothesized an etiologic association between altered platelet counts and postdonation splenomegaly and sought to explore this...
7.
Curry M, Forns X, Chung R, Terrault N, Brown Jr R, Fenkel J, et al.
Gastroenterology
. 2014 Sep;
148(1):100-107.e1.
PMID: 25261839
Background & Aims: Patients with detectable hepatitis C virus (HCV) RNA at the time of liver transplantation universally experience recurrent HCV infection. Antiviral treatment before transplantation can prevent HCV recurrence,...
8.
Muir A, Arora S, Everson G, Flisiak R, George J, Ghalib R, et al.
J Hepatol
. 2014 Jul;
61(6):1238-46.
PMID: 25064437
Background & Aims: Peginterferon lambda-1a (Lambda) is a type-III interferon with similar antiviral activity to alfa interferons but with a diminished extrahepatic receptor distribution, reducing the risk for extrahepatic adverse...
9.
Everson G, Cooper C, Hezode C, Shiffman M, Yoshida E, Beltran-Jaramillo T, et al.
Liver Int
. 2014 Feb;
35(1):108-19.
PMID: 24517252
Background & Aims: Danoprevir is a hepatitis C virus (HCV) protease inhibitor with activity against genotypes (G)1/G4, which is maintained at lower doses by ritonavir-boosting. We report results of a...
10.
Jacobson I, Gordon S, Kowdley K, Yoshida E, Rodriguez-Torres M, Sulkowski M, et al.
N Engl J Med
. 2013 Apr;
368(20):1867-77.
PMID: 23607593
Background: Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to...